Posted by Michael Wonder on 07 Dec 2020
Health economic assessment of Beovu in wet age-related macular degeneration
4 December 2020 - TLV has produced a health economic assessment for the regions for Beovu (brolucizumab).
TLV considers that Eylea, Lucentis and Avastin are relevant comparison alternatives to Beovu. TLV's health economic assessment is based on a cost comparison between Beovu and Eylea, Lucentis and Avastin.
